For instance, studies assessing the presence of cryptic exons at different levels of TDP-43 knockdown in vitro, or in patients with or post-mortem tissue from varying clinical stages of ALS-FTD, could allow curation of a database reflecting which cryptic exons appear early and late in disease. The gene discussed is TARDBP; the disease is frontotemporal dementia.